Telephone Titration of Heart Failure Medications

被引:10
|
作者
Steckler, Anne E. [3 ]
Bishu, Kalkidan
Wassif, Heba
Sigurdsson, Gardar
Wagner, Judy [3 ]
Jaenicke, Connie [3 ]
Vats, Shashank
Rector, Thomas
Anand, Inder S. [1 ,2 ]
机构
[1] VA Med Ctr, Heart Failure Program, Minneapolis, MN 55417 USA
[2] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
[3] VA Med Ctr, CHF TeleHlth Clin, Minneapolis, MN 55417 USA
关键词
disease management; heart failure; nurse-managed clinic; telephone care; LEFT-VENTRICULAR DYSFUNCTION; RANDOMIZED-TRIAL; MYOCARDIAL-INFARCTION; DISEASE MANAGEMENT; MERIT-HF; CARVEDILOL; BLOCKER; MORBIDITY; MORTALITY; SURVIVAL;
D O I
10.1097/JCN.0b013e3181ec1223
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In clinical practice, heart failure (HF) medications are underused and prescribed at lower than recommended doses. Telephone care is an option that could help to titrate HF medication in a timely manner. We describe our experience of a nurse-run, cardiologist-or nurse practitioner-supervised clinic to up-titrate HF medications via telephone. Methods: Patients with the diagnosis of HF, New York Heart Association classes I to III, were referred to a registered nurse-run, cardiologist-/nurse practitioner-supervised HF medication titration clinic. Clinical and medication data collected at enrollment to the clinic and at 3 to 6 months after optimization of HF medications in patients who did or did not reach the target doses were compared. Effect on left ventricular (LV) function was also evaluated. Results: There were 79 patients in the evaluation: 64 with HF and LV systolic dysfunction (LVSD) and the remaining 15 with HF and preserved ejection fraction (EF). Seventy-two percent of patients with LVSD were on an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), and 61% were on a beta-blocker at baseline, and this increased to 98% and 97%, respectively, after optimization. Target doses was achieved in 50% of patients for ACEI or ARB, and in 41% for beta-blockers. The median time to optimization was 54 days (interquartile range, 20-97 days). The average number of phone calls at the time of optimization were 5.4 (SD, 3.7), and the average number of clinic visits was 1.9 (SD, 1.3). Reasons for not reaching the target doses included hypotension, hyperkalemia, and renal dysfunction for ACEI and bradycardia for beta-blockers. Overall, the EF increased by 10% (SD, 10%) after 6 months, and 35% or greater in 42% of patients whose baseline EF was less than 35%. There were no adverse events related to the dose up-titration. Conclusion: Telephonic titration of HF medications was feasible and safe and was achieved in 97% patients on ACEI/ARB and beta-blockers. Medication titration was associated with significant improvement in LV function, avoiding the need for device therapy in many patients.
引用
收藏
页码:29 / 36
页数:8
相关论文
共 50 条
  • [31] Impact of telephone support to patients with heart failure risk
    Padilla Just, M. Neus
    Capilla Tomas, Sergi
    Laorden Mas, Helena
    Fabrellas Padres, Nuria
    Coidures Charles, Alicia
    Marti Aguasca, M. Luisa
    INTERNATIONAL JOURNAL OF INTEGRATED CARE, 2011, 11
  • [32] Titration of beta-blockers in heart failure patients
    Luzier, A
    Antell, LA
    Chang, LL
    Xuan, JW
    Roth, DA
    CIRCULATION, 2001, 104 (17) : 717 - 718
  • [33] Drug titration by nursing professionals in heart failure units
    Manuel Civera, Jose
    Conesa, Adriana
    Villaescusa, Amparo
    Nunez, Julio
    REVISTA ESPANOLA DE CARDIOLOGIA, 2021, 74 (06): : 561 - 561
  • [34] Effects of a diuretic titration protocol in heart failure patients
    Prasun, M
    Kocheril, A
    Klass, P
    Dunlap, S
    Piano, MR
    CIRCULATION, 2002, 106 (19) : Q - Q
  • [35] The burden of frailty in heart failure: Prevalence, impacts on clinical outcomes and the role of heart failure medications
    Lai, Hsi-Yu
    Huang, Shih-Tsung
    Anker, Stefan D.
    von Haehling, Stephan
    Akishita, Masahiro
    Arai, Hidenori
    Chen, Liang-Kung
    Hsiao, Fei-Yuan
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2024, 15 (02) : 660 - 670
  • [36] Emergency Department Use of Heart Failure-Exacerbating Medications in Patients with Chronic Heart Failure
    Casey, Martin F.
    Hallmark, Joy
    Chang, Patricia P.
    Rodgers, Jo E.
    Mehta, Aakash
    Chari, Srihari V.
    Skersick, Preston
    Bohrmann, Thomas
    Goyal, Parag
    Meyer, Michelle L.
    DRUG SAFETY, 2024, 47 (12) : 1225 - 1234
  • [37] ADMITTING TEAM IMPACTS USE OF HEART FAILURE MEDICATIONS IN PATIENTS ADMITTED WITH HEART FAILURE EXACERBATION
    Hawson, J. J.
    Eskandari, M.
    Saito, M.
    Negishi, K.
    Koneru, S.
    Moore, A.
    Foster, S.
    Power, J.
    Dwyer, N.
    Marwick, T. H.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 31 - 31
  • [38] Effect of Intensive Nurse-Led Optimization of Heart Failure Medications in Patients With Heart Failure
    Driscoll, Andrea
    Meagher, Sharon
    Kennedy, Rhoda
    Currey, Judy
    JOURNAL OF CARDIOVASCULAR NURSING, 2024, 39 (05) : 417 - 426
  • [39] Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission
    Cotter, Gad
    Deniau, Benjamin
    Davison, Beth
    Edwards, Christopher
    Adamo, Marianna
    Arrigo, Mattia
    Barros, Marianela
    Biegus, Jan
    Celutkiene, Jelena
    Cerlinskaite-Bajore, Kamile
    Chioncel, Ovidiu
    Cohen-Solal, Alain
    Damasceno, Albertino
    Diaz, Rafael
    Filippatos, Gerasimos
    Gayat, Etienne
    Kimmoun, Antoine
    Lam, Carolyn S. P.
    Metra, Marco
    Novosadova, Maria
    Pang, Peter S.
    Pagnesi, Matteo
    Ponikowski, Piotr
    Saidu, Hadiza
    Sliwa, Karen
    Takagi, Koji
    Ter Maaten, Jozine M.
    Tomasoni, Daniela
    Voors, Adriaan
    Mebazaa, Alexandre
    JAMA CARDIOLOGY, 2024, 9 (02) : 114 - 124
  • [40] Why heart failure medications are altered during non-heart failure related admissions?
    Jafari, Y. Yasmine
    Mc Donald, K. M.
    Halley, C. H.
    Barret, M. B.
    O'donoghue, E. O.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 372 - 373